REFERENCES
- Egan K M, Seddon J M, Glynn R J, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32(4)239–251, [INFOTRIEVE], [CSA]
- Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72: 2219–2213, [INFOTRIEVE], [CSA], [CROSSREF]
- Tang C K, Gong X Q, Moscatello D K, et al. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000; 60(11)3081–3087, [INFOTRIEVE], [CSA]
- Pietrzkowski Z, Lammers R, Carpenter G, et al. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ 1992; 3(4)199–205, [INFOTRIEVE], [CSA]
- Nathanson S D, Slater R, Debruyn D, et al. Her-2/neu expression in primary breast cancer with sentinel lymph node metastasis. Ann Surg Oncol 2006; 13(2)205–213, [INFOTRIEVE], [CSA], [CROSSREF]
- Song H, Sondak V K, Barber D L, et al. Modulation of Janus kinase 2 by cisplatin in cancer cells. Int J Oncol 2004; 24(4)1017–1026, [INFOTRIEVE], [CSA]
- Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21(46)7001–7010, [INFOTRIEVE], [CSA], [CROSSREF]
- Khandwala H M, McCutcheon I E, Flyvbjerg A, Friend K E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21(3)215–244, [INFOTRIEVE], [CSA], [CROSSREF]
- Pollak M N. Insulin-like growth factors and neoplasia. Novartis Found Symp 2004; 262: 84–98, [INFOTRIEVE], [CSA]
- Pollak M N, Schernhammer E S, Hankinson S E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4(7)505–518, [INFOTRIEVE], [CSA], [CROSSREF]
- Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 2003; 22(42)6589–6597, [INFOTRIEVE], [CSA], [CROSSREF]
- Hakam A, Yeatman T J, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1993; 30: 1128–1133, [CSA], [CROSSREF]
- Kanter-Lewensohn L, Dricu A, Girnita L, et al. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors 2000; 17: 193–202, [INFOTRIEVE], [CSA]
- Khandwala H M, McCutcheon I E, Flyvbjerg A, Friend K E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215–244, [INFOTRIEVE], [CSA], [CROSSREF]
- Turner B C, Haffty B G, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079–3083, [INFOTRIEVE], [CSA]
- Ericsson C, Girnita L, Seregard S, et al. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002; 43(1)1–8, [CSA]
- Economou M A, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci 2005; 46(12)4372–4375, [INFOTRIEVE], [CSA], [CROSSREF]
- Kang D C, Motwani M, Fisher P B. Role of the transcription factor AP-1 in melanoma differentiation (review). Int J Oncol 1998; 13(6)1117–1126, [INFOTRIEVE], [CSA]
- Krishnakumar S, Abhyankar D, Lakshmi S A, et al. HLA expression in choroidal melanomas: correlation with clinicopathological features. Curr Eye Res 2004; 28(6)409–416, [INFOTRIEVE], [CSA], [CROSSREF]
- Onken M D, Worley L A, Ehlers J P, Harbour J W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64(20)7205–7209, [INFOTRIEVE], [CSA], [CROSSREF]
- Krishnakumar S, Mallikarjuna K, Desai N, et al. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol 2004; 88(12)1521–1526, [INFOTRIEVE], [CSA], [CROSSREF]
- Chakravarti A, Loeffler J S, Dyson N J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62(1)200–207, [INFOTRIEVE], [CSA]
- Steinbach J P, Eisenmann C, Klumpp A, Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun 2004; 321(3)524–530, [INFOTRIEVE], [CSA], [CROSSREF]
- Warshamana-Greene G S, Litz J, Buchdunger E, et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 2004; 3(5)527–535, [INFOTRIEVE], [CSA]
- Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93(24)1852–1857, [INFOTRIEVE], [CSA], [CROSSREF]
- Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 2002; 8(12)BR521–BR526, [INFOTRIEVE], [CSA]